1
|
McLean AN, Bicknell SR, McAlpine LG and
Peacock AJ: Investigation of pleural effusion: an evaluation of the
new Olympus LTF semiflexible thoracofiberscope and comparison with
Abram’s needle biopsy. Chest. 114:150–153. 1998.PubMed/NCBI
|
2
|
Kaburagi T, Kuroda H and Amemiya R:
Thoracoscopy under local anesthesia focusing on findings of
carcinomatous pleurisy. Kikanshigaku (J Jpn Society Bronchology).
26:326–330. 2004.
|
3
|
Canto A, Rivas J, Saumench J, Morera R and
Moya J: Points to consider when choosing a biopsy method in cases
of pleurisy of unknown origin. Chest. 84:176–179. 1983. View Article : Google Scholar : PubMed/NCBI
|
4
|
Pavlidis N, Briasoulis E, Hainsworth J and
Greco FA: Diagnostic and therapeutic management of cancer of an
unknown primary. Eur J Cancer. 39:1990–2005. 2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Casal RF, Eapen GA, Morice RC and Jimenez
CA: Medical thoracoscopy. Curr Opin Pulm Med. 15:313–320. 2009.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Narushima M, Matsuishi J, Yamashita J and
Suzuki H: Current situations of medical thoracoscopy for pleural
deseases in Japan. Kikanshigaku (J Jpn Society Bronchology).
26:711–716. 2004.
|
7
|
Johnston WW: The malignant pleural
effusion. A review of cytopathologic diagnoses of 584 specimens
from 472 consecutive patients. Cancer. 56:905–909. 1985. View Article : Google Scholar : PubMed/NCBI
|
8
|
Kobayashi Y, Terauchi F, Nishi H, Fujitou
A, Itou H and Isaka K: A case of advanced ovarian cancer upstaged
on the bases of pleural washing cytology. J Obstet Gynaecol Res.
35:588–592. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Fukuoka T, Matsuoka E, Chiba S, Takayama S
and Ohono S: Ovarian cancer that was initially diagnosed as
malignant pleural effusion of unknown primary origin. J Rural Med.
4:41–44. 2009. View
Article : Google Scholar
|
10
|
Chernow B and Sahn SA: Carcinomatous
involvement of the pleura: an analysis of 96 patients. Am J Med.
63:695–702. 1977. View Article : Google Scholar : PubMed/NCBI
|
11
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
12
|
Nystrom JS, Weiner JM,
Heffelfinger-Juttner J, Irwin LE, Bateman JR and Wolf RM:
Metastatic and histologic presentations in unknown primary cancer.
Semin Oncol. 4:53–58. 1977.PubMed/NCBI
|
13
|
Topalak O, Saygili U, Soyturk M, et al:
Serum, pleural effusion, and ascites CA-125 levels in ovarian
cancer and nonovarian benign and malignant diseases: a comparative
study. Gynecol Oncol. 85:108–113. 2002. View Article : Google Scholar : PubMed/NCBI
|
14
|
Matsunaga T, Hiraiwa T, Kodaira H and Imai
K: KL-6 is useful tumor marker for ovarian cancer. Nihon Fujinka
Shyuyou Gakkai Zasshi (Jpn J Gynecol Oncol). 26:387–393. 2008.
|
15
|
Kohno N, Akiyama M, Kyoizumi S, Hakoda M,
Kobuke K and Yamakido M: Detection of soluble tumor-associated
antigens in sera and effusions using novel monoclonal antibodies,
KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol.
18:203–216. 1988.PubMed/NCBI
|
16
|
Miyazaki K, Kurishima K, Kagohashi K, et
al: Serum KL-6 levels in lung cancer patients with or without
interstitial lung disease. J Clin Lab Anal. 24:295–299. 2010.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Ohnishi H, Yokoyama A, Kondo K, et al:
Comparative study of KL-6, surfactant protein-A, surfactant
protein-D, and monocyte chemoattractant protein-1 as serum markers
for interstitial lung diseases. Am J Respir Crit Care Med.
165:378–381. 2002. View Article : Google Scholar : PubMed/NCBI
|